Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8% – What’s Next?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) rose 10.8% on Thursday . The company traded as high as $54.48 and last traded at $55.6050. Approximately 279,959 shares changed hands during trading, a decline of 73% from the average daily volume of 1,043,011 shares. The stock had previously closed at $50.17.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Stifel Nicolaus upped their price objective on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Finally, HC Wainwright dropped their price objective on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.00.

Structure Therapeutics Stock Performance

The firm’s 50 day moving average price is $66.17 and its 200-day moving average price is $52.16. The firm has a market capitalization of $3.75 billion, a PE ratio of -66.96 and a beta of -1.16.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP grew its stake in Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after acquiring an additional 1,432,797 shares during the period. Avoro Capital Advisors LLC raised its position in Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after acquiring an additional 1,150,000 shares during the period. Janus Henderson Group PLC lifted its holdings in Structure Therapeutics by 14.4% during the fourth quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock valued at $354,006,000 after purchasing an additional 641,322 shares in the last quarter. BVF Inc. IL grew its position in shares of Structure Therapeutics by 8.6% in the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after purchasing an additional 275,105 shares during the period. Finally, Morgan Stanley increased its stake in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after purchasing an additional 1,510,093 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.